Immunocore Holdings plc (NASDAQ:IMCR – Free Report) – Research analysts at Leerink Partnrs raised their FY2024 earnings per share estimates for shares of Immunocore in a research report issued on Wednesday, November 6th. Leerink Partnrs analyst J. Chang now expects that the company will earn ($1.48) per share for the year, up from their previous estimate of ($2.20). The consensus estimate for Immunocore’s current full-year earnings is ($1.71) per share. Leerink Partnrs also issued estimates for Immunocore’s Q4 2024 earnings at ($0.93) EPS and FY2025 earnings at ($2.59) EPS.
Immunocore (NASDAQ:IMCR – Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.50. The firm had revenue of $80.25 million during the quarter, compared to analyst estimates of $78.94 million. Immunocore had a negative return on equity of 12.98% and a negative net margin of 15.87%. The company’s revenue was up 23.7% on a year-over-year basis. During the same period last year, the company earned ($0.59) earnings per share.
Check Out Our Latest Stock Analysis on IMCR
Immunocore Price Performance
Shares of IMCR stock opened at $34.69 on Friday. The firm’s 50 day moving average price is $32.64 and its two-hundred day moving average price is $39.52. The company has a debt-to-equity ratio of 1.31, a quick ratio of 5.15 and a current ratio of 5.17. The stock has a market cap of $1.74 billion, a PE ratio of -36.52 and a beta of 0.72. Immunocore has a 52-week low of $29.72 and a 52-week high of $76.98.
Institutional Trading of Immunocore
Several institutional investors and hedge funds have recently bought and sold shares of IMCR. Primecap Management Co. CA grew its stake in shares of Immunocore by 26.7% in the third quarter. Primecap Management Co. CA now owns 2,472,020 shares of the company’s stock valued at $76,954,000 after buying an additional 520,950 shares in the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Immunocore by 7.5% during the third quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 427,152 shares of the company’s stock worth $13,297,000 after purchasing an additional 29,689 shares during the period. GSA Capital Partners LLP acquired a new position in Immunocore during the third quarter worth approximately $406,000. Crossmark Global Holdings Inc. bought a new stake in Immunocore in the third quarter valued at approximately $866,000. Finally, Assetmark Inc. lifted its position in shares of Immunocore by 6.5% in the third quarter. Assetmark Inc. now owns 30,555 shares of the company’s stock valued at $951,000 after buying an additional 1,878 shares during the last quarter. Institutional investors own 84.50% of the company’s stock.
About Immunocore
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
See Also
- Five stocks we like better than Immunocore
- What Are Dividends? Buy the Best Dividend Stocks
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Comparing and Trading High PE Ratio Stocks
- MarketBeat Week in Review – 11/4 – 11/8
- Investing in Travel Stocks Benefits
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.